Robert McCormack, PhD

Robert McCormack, PhD, head, Technology Innovation, Janssen Diagnostics, LLC, discusses the SWOG S0500 study, which evaluated different treatments in patients with metastatic breast cancer who had elevated circulating tumor cell (CTC) levels.